Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390210 | 1.00 | TLR4 (0.31) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL21561696 | 1.00 | TLR4 (0.31) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL26029378 | 1.00 | TLR4 (0.31) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL1644158 | 0.85 | — | — | |
| SCHEMBL1643468 | 0.85 | — | — | |
| SCHEMBL10005826 | 0.85 | — | — | |
| SCHEMBL19608815 | 0.85 | — | — | |
| SCHEMBL18533037 | 0.82 | — | — | |
| SCHEMBL8059872 | 0.81 | LGALS8 (0.34) | TLR4LY96CYP2C19HIF1A | |
| SCHEMBL26029389 | 0.81 | LGALS8 (0.34) | TLR4LY96CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370668-B2 | Manufacture of antisense oligomers and conjugates targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| US-20170015697-A1 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE | SANTARIS PHARMA A/S (DK) | 2017-01-19 | — | — | US | disclosed |
| WO-2010000665-A1 | ANTIDOTE OLIGOMERS | SANTARIS PHARMA A/S (DK) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009109665-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | SANTARIS PHARMA A/S (DK) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370668-B2 | Manufacture of antisense oligomers and conjugates targeting PCSK9 | PCSK9, PCSK7, PCSK6 | TLR4 3757/4885LY96 4032/4885CYP2C19 4659/4885 |
| US-20170015697-A1 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE | TNFRSF1A, TNFRSF9, CD40 | TLR4 524/4885LY96 889/4885CYP2C19 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.